DALLAS, May 20, 2004 (PRIMEZONE) -- The Wall Street Small Cap Reporter, a leading source of news and information for the small cap investor, reported last week that the strongest opportunities for significant gains in the medical device space appear to be among the sector's small cap companies. This week, we are closely monitoring a handful of OTC companies that have demonstrated strong volume in recent weeks and may be poised for short-term growth.
Cell Bio-Systems, Inc. (Pink Sheets:CBSI) earns The Wall Street Small Cap Reporter's highest rating of "Strong Buy" in this space. Shares of CBSI closed yesterday at $1.25, and have proven that they can climb to $1.90 in recent weeks. The Wall Street Small Cap Reporter believes CBSI should continue attracting interest at its current price level.
Cell Bio-Systems is the exclusive licensee of two patented syringe connection products that it plans to adapt as disposable cannulas for liposuction and other living tissue procedures. Popularized by its use to insert or extract tissue during liposuction and collagen implant procedures, a cannula is an enclosed tubular device, currently made from stainless steel, that looks much like a large needle. Though re-sterilized, steel cannulas are reused in hundreds of procedures, typically for as long as two years or more. Despite safety concerns and procedural complications regularly ascribed to steel cannulas, no comparable, disposable device currently exists. CBSI is developing an affordable, disposable product line that will fill this void.
The Wall Street Small Cap Reporter has identified four other "stocks to watch" in this space. They are: Computerized Thermal Imaging, Inc. (Pink Sheets:COIB), a manufacturer of thermal imaging and infrared devices used in clinical diagnosis and pain management; Antares Pharma (OTCBB:ANTR) a developer of specialty pharmaceutical products; Imaging Diagnostic Systems (OTCBB:IMDS), owner of the first, patented CT laser breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross-sectional images of the human breast; and trading heavily on significant revenue growth this year, Cambridge Heart (OTCBB:CAMH), a developer of products for the non-invasive diagnosis of heart disease.
The Wall Street Small Cap Reporter believes many aggressive investors will want to consider these companies on recent news and volume.
For Information contact: 866-249-4961
-- Important Notice and Disclaimer: Please Read --
Legal Notice Regarding Forward-Looking Statements: "Forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. Cell Bio-Systems disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions (including in the information technology and financial information industry), actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services, and changes in our business strategies.